Osteopenia News and Research

RSS

Osteopenia is a condition where bone mineral density is lower than normal. It is considered by many doctors to be a precursor to osteoporosis. However, not every person diagnosed with osteopenia will develop osteoporosis. More specifically, osteopenia is defined as a bone mineral density T-score between -1.0 and -2.5.

Studies show vitamin D may benefit cardiovascular, skin and metabolic disorders

The Endocrine Society's new scientific statement published online today represents the first comprehensive evaluation of both the basic and clinical evidence related to the non-skeletal effects of vitamin D. The statement addresses current research regarding the associations of vitamin D with immune function, hypertension, stroke, skin conditions and maternal/fetal health.

19 May 2012

Tarsa advances OSTORA NDA filing through $28M Series B financing

Tarsa Therapeutics, Inc. today announced completion of a $28 million Series B equity financing led by new investor Foresite Capital.

17 Mar 2012

Telephone-based counseling program does not improve osteoporosis medication adherence

Telephone motivational counseling sessions did not result in a statistically significant improvement in adherence to an osteoporosis medication regimen, according to a report published Online First by Archives of Internal Medicine, one of the JAMA/Archives journals.

28 Feb 2012

Research roundup: 'No individual mandate' scenarios; Breaking down health care expenditures

This paper expands 2011 research examining whether the health law's controversial individual mandate – which requires most people to have health insurance -- will be effective.

21 Jan 2012

Testing for osteoporosis – how often?

A new study shows that many women who get screened for osteoporosis may not need it. It suggests that the current guidelines result in too many unnecessary tests, increasing costs and sometimes spurring unnecessary treatment.

19 Jan 2012

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Viread in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients ages 2-12.

19 Jan 2012

Growth hormone replacement increases bone formation in abdominally obese women

In a new study presented today at the annual meeting of the Radiological Society of North America (RSNA), growth hormone replacement for six months was found to increase bone formation in abdominally obese women.

29 Nov 2011

Many spinal fusion surgery patients have low levels of vitamin D

A new study indicates that many patients undergoing spine surgery have low levels of vitamin D, which may delay their recovery. In a study of 313 patients undergoing spinal fusion surgery, orthopaedic surgeons at Washington University School of Medicine in St. Louis found that more than half had inadequate levels of vitamin D, including one-fourth who were more severely deficient.

3 Nov 2011

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced new data from STEPS 2, a long-term open-label study, showing that GATTEX (teduglutide) was associated with achieving and maintaining clinically meaningful reductions in parenteral nutrition (PN) and intravenous (IV) fluid volume in adult subjects with short bowel syndrome.

1 Nov 2011

Tarsa reports positive data from OSTORA Phase III ORACAL trial for postmenopausal osteoporosis

Tarsa Therapeutics today reported that it presented positive safety and efficacy data from its Phase III ORACAL trial of OSTORA, the company's oral recombinant salmon calcitonin tablet in development for the treatment of postmenopausal osteoporosis.

19 Sep 2011

Positive data from Tarsa's OSTORA Phase III trial on postmenopausal osteoporosis

Tarsa Therapeutics today presented positive safety and efficacy data from its Phase III ORACAL trial of OSTORA-, the company's oral recombinant salmon calcitonin tablet in development for the treatment of postmenopausal osteoporosis.

19 Sep 2011

FDA reviews safety issues of bisphosphonates for osteoporosis

An advisory committee for U.S. Food and Drug Administration meets Friday to review the safety of a popular class of osteoporosis drugs called bisphosphonates amid worry that their long-term use could cause rare fractures of the thighbones and affect the jawbone. The committee will evaluate whether women should temporarily stop using the drugs or use them for only a few years.

6 Sep 2011

NPS submits NDA CMC section to FDA for GATTEX

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announced that it has submitted the chemistry, manufacturing and controls (CMC) section of its new drug application (NDA) for GATTEX® (teduglutide) to the U.S. Food and Drug Administration (FDA).

18 Aug 2011

FDA approves Gilead's Complera for treatment of HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Complera, a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults.

11 Aug 2011

Unigene second quarter revenue decreases to $2.5 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced second quarter financial results for the period ended June 30, 2011. The Company highlighted significant progress achieved in the second quarter with the continued execution of its turnaround strategy.

8 Aug 2011

Osteoporosis, low bone density common in people with early-stage MS

Osteoporosis and low bone density are common in people in the early stages of multiple sclerosis (MS), according to a new study published in the July 12, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

12 Jul 2011

Varicocele surgery may increase testosterone production

17 Jun 2011

Low testosterone linked to varicoceles

As many as 15 percent of men have varicoceles, masses of enlarged and dilated veins in the testicles. There is new evidence that varicoceles, long known to be a cause of male infertility, interfere with the production of testosterone -- a crucial hormone to maintaining men's health. There is good news too: Microsurgery can increase testosterone levels in these men. Results of new research by physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center are in a recent edition of BJU International.

16 Jun 2011

$Zoledronate at lower dose effective in reducing risk of osteoporotic fractures$

Zoledronate at lower dose effective in reducing risk of osteoporotic fractures

A lower dose of zoledronic acid than currently recommended for prevention of bone fractures due to osteoporosis decreases bone resorption and increases bone density, and may be effective in reducing the risk of osteoporotic fractures, a study finds.

7 Jun 2011

The Endocrine Society releases clinical practice guideline on Vitamin D deficiency

Today, The Endocrine Society released "Evaluation, Treatment, and Prevention of Vitamin D Deficiency: An Endocrine Society Clinical Practice Guideline." The clinical practice guideline (CPG) is published in the July 2011 issue of the Journal of Clinical Endocrinology & Metabolism (JCEM), a publication of The Endocrine Society.

7 Jun 2011